Sentinel Oncology Ltd. and Oncothyreon Inc. have entered a collaboration agreement for the development of Sentinel’s Checkpoint Kinase 1 (Chk1) program. Oncothyreon will fund additional research at Sentinel directed for the Chk1 target, and will have an exclusive license to develop and commercialize any resulting compounds. Sentinel is eligible to receive preclinical, clinical and commercial milestone payments of as much as $174 million, and royalties on sales.   Sentinel has developed a series ...